Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages 683-691

  Liu, Jianqiang ^a,b   Gao, Jun ^a   Du, Yiqi ^a   Li, Zhaoshen ^a   Ren, Yan ^a   Gu, Junjun ^a   Wang, Xiaowei ^a   Gong, Yanfang ^a   Wang, Weiwei ^a   Kong, Xiangyu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

Author keywords

diagnosis; microRNAs; pancreatic cancer; plasma

Indexed keywords

CA 19-9 ANTIGEN; MICRORNA; MICRORNA 155; MICRORNA 16; MICRORNA 181A; MICRORNA 181B; MICRORNA 196A; MICRORNA 21; MICRORNA 210; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SCREENING; CANCER STAGING; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RNA EXTRACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861578195     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26422     Document Type: Article

References (49)

1. Real FX,. A catastrophic hypothesis for pancreas cancer progression. Gastroenterology 2003; 124: 1958-64.
2. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD,. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-79.
3. Shimizu Y, Yasui K, Matsueda K, Yanagisawa A, Yamao K,. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005; 20: 1591-4.
4. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, Yamaguchi T, Izawa K, Tsunoda T, Yoshino R, Eto T,. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203: 77-81.
5. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
6. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M,. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008; 12: 2171-6.
7. Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, Jing Q, Qin Y, Li Z,. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma Patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci 2011; 56: 602-9.
8. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462-9.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
10. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM,. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-8.
11. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C,. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 2009; 33: 698-709.
12. Kawarada Y,. New classification of pancreatic carcinoma - Japan Pancreas Society. Nippon Shokakibyo Gakkai Zasshi 2003; 100: 974-80.
13. Sobin LH, Wittekind C,. TNM classification of malignant tumors, 6th edn. New York: John Wiley, 2002: 93-6.
14. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q,. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-66.
15. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R,. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000; 89: 83-8.
16. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P,. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005; 31: 164-9.
17. Schmiegel WH, Kreiker C, Eberl W, Arndt R, Classen M, Greten H, Jessen K, Kalthoff H, Soehendra N, Thiele HG,. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut 1985; 26: 456-60.
18. Matsugi S, Hamada T, Shioi N, Tanaka T, Kumada T, Satomura S,. Serum carboxypeptidase A activity as a biomarker for early-stage pancreatic carcinoma. Clin Chim Acta 2007; 378: 147-53.
19. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM,. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006; 24: 252-8.
20. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD,. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34: 436-43.
21. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10: 2386-92.
22. Joergensen MT, Brunner N, De Muckadell OB,. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res 2010; 30: 587-92.
23. Patwa TH, Zhao J, Anderson MA, Simeone DM, Lubman DM,. Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multi-lectin fluorescence detection. Anal Chem 2006; 78: 6411-21.
24. Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K,. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 2010; 45: 52-9.
25. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M,. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 487-91.
26. Marchese R, Muleti A, Pasqualetti P, Bucci B, Stigliano A, Brunetti E, De Angelis M, Mazzoni G, Tocchi A, Brozzetti S,. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 2006; 32: 171-7.
27. Matsubayashi H, Canto M, Sato N, Klein A, Abe T, Yamashita K, Yeo CJ, Kalloo A, Hruban R, Goggins M,. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006; 66: 1208-17.
28. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM,. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007; 6: 641-5.
29. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K,. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 2006; 141: 968-73.
30. Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y, Xuezhi W,. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002; 25: 336-41.
31. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M,. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12: 442-6.
32. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G,. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010; 28: 655-61.
33. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, Goel A,. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-74.
34. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694.
35. Taylor DD, Gercel-Taylor C,. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
36. Kong X, Du Y, Li L, Liu J, Wang G, Zhu J, Man X, Gong Y, Xiao L, Zheng Y,. Plasma miR-216a as a potential marker of pancreatic injury in a rat model of acute pancreatitis. World J Gastroenterol 2010; 16: 4599-604.
37. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, Zupan M, Canuet M, Grunebaum L, Brunette A, Desprez D, Chabot F, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177: 536-43.
38. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J,. Cancer: a systems biology disease. Biosystems 2006; 83: 81-90.
39. Iwamura T, Katsuki T,. Kinetics of carcinoembryonic antigen and carbohydrate antigen 19-9 production in a human pancreatic cancer cell line (SUIT-2). Gastroenterol Jpn 1987; 22: 640-6.
40. Sakahara H, Endo K, Nakajima K, Nakashima T, Koizumi M, Ohta H, Hidaka A, Kohno S, Nakano Y, Naito A, Suzuki T, Torizuka K,. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57: 1324-6.
41. Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL,. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997; 4: 551-6.
42. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD,. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046-54.
43. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM,. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-84.
44. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H,. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126: 73-80.
45. Mardin WA, Mees ST,. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol 2009; 16: 3183-9.
46. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC,. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 2011; 128: 132-43.
47. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-7.
48. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
49. Bansal P, Sonnenberg A,. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995; 109: 247-51.